-
支原体肺炎是临床上常见的儿童呼吸道疾病,是由肺炎支原体引起的急性肺部炎症,临床症状表现为咳嗽、发热,部分患儿经过常规对症治疗后其临床症状仍持续性加重,逐渐发展为重症肺炎,病情严重时会导致全身并发症,严重危及患儿的生命安全[1-2]。研究[3]发现,甲泼尼龙琥珀酸钠在治疗肺炎中的效果良好。本研究旨在探讨常规对症治疗基础上给予甲泼尼龙琥珀酸钠对儿童重症支原体肺炎的疗效及对炎性因子的影响。现作报道。
-
观察组患儿退热时间、咳嗽消失时间、肺部啰音消失时间均明显短于对照组(P < 0.01)(见表 1)。
分组 n 退热时间/d 咳嗽消失时间/d 肺部啰音消失时间/d 观察组 30 1.40±0.75 3.31±1.28 2.27±0.69 对照组 30 3.11±1.24 4.35±1.30 4.52±1.39 t — 7.26 3.78 7.94 P — < 0.01 < 0.01 < 0.01 表 1 2组患儿临床症状改善情况比较(x±s)
-
治疗前2组患儿CRP、IL-6、TNF-α、IFN-γ水平差异均无统计学意义(P>0.05);治疗后2组患儿CRP、IL-6、TNF-α、IFN-γ水平均低于治疗前(P < 0.05),且研究组患儿CRP、IL-6、TNF-α、IFN-γ水平均低于对照组(P < 0.05~P < 0.01)(见表 2)。
分组 n CRP/(mg/L) IL-6/(ng/L) TNF-α/(mg/L) IFN-γ/(ng/L) 治疗前 研究组 30 45.49±10.15 17.04±2.28 2.20±0.14 102.58±16.35 对照组 30 45.73±9.94 17.23±2.09 2.21±0.17 100.94±15.84 t — 0.09 0.34 0.25 0.39 P — >0.05 >0.05 >0.05 >0.05 治疗后 研究组 30 12.7±3.5* 7.21±0.66* 1.31±0.10* 82.89±11.06* 对照组 30 17.4±5.7* 11.32±1.07* 1.75±0.13* 90.12±13.87* t — 3.85 17.91 14.69 2.23 P — < 0.01 < 0.01 < 0.01 < 0.05 组内配对t检验:*P < 0.05 表 2 2组患儿炎性因子水平比较(x±s)
甲泼尼龙琥珀酸钠治疗儿童重症支原体肺炎的疗效及对炎症因子的影响
Effect of methylprednisolone sodium succinate in the treatment of severe mycoplasma pneumonia in children and its effects on inflammatory factors
-
摘要:
目的探讨甲泼尼龙琥珀酸钠对比常规对症治疗儿童重症支原体肺炎的疗效及对炎性因子的影响。 方法选择重症支原体肺炎患儿60例,采用随机数字表法将病人分为研究组与对照组,各30例。对照组采用常规对症治疗,研究组在对照组基础上结合甲泼尼龙琥珀酸钠治疗。比较2组临床症状改善情况,治疗前后血清中白细胞介素-6(IL-6)、肿瘤坏死因子α(TNF-α)、干扰素γ(IFN-γ)及C反应蛋白(CRP)水平。 结果观察组患儿退热时间、咳嗽消失时间、肺部啰音消失时间均明显短于对照组(P < 0.01)。治疗前2组患儿CRP、IL-6、TNF-α、IFN-γ水平差异均无统计学意义(P>0.05);治疗后2组患儿CRP、IL-6、TNF-α、IFN-γ水平均低于治疗前(P < 0.05),且研究组患儿CRP、IL-6、TNF-α、IFN-γ水平均低于对照组(P < 0.05~P < 0.01)。 结论在常规对症治疗基础上给予甲泼尼龙琥珀酸钠辅助治疗,可有效改善重症支原体肺炎患儿的临床症状,促进炎性因子及CRP水平下降,降低炎症反应,疗效显著。 Abstract:ObjectiveTo investigate the effects of methylprednisolone sodium succinate in the treatment of severe mycoplasma pneumonia, and its influence on inflammatory factors in children. MethodsSixty children with severe mycoplasma pneumonia were divided into the study group and control group according to the random umber table method(50 cases in each group).The control group was treated with conventional symptomatic treatment, while the study group was treated with methylprednisolone sodium succinate on the basis of the control group.The clinical symptoms improvement, and serum levels of interleukin-6(IL-6), tumor necrosis factor α(TNF-α), interferon γ(IFN-γ) and C-reactive protein(CRP) before and after treatment were compared between two groups. ResultsThe time of fever abatement, cough disappearance and lung rales disappearance in study group were significantly shorter than those in control group(P < 0.01).Before treatment, there was no statistical significance in the levels of CRP, IL-6, TNF-α and IFN-γ between two groups(P>0.05).After treatment, the levels of CRP, IL-6, TNF-α and IFN-γ in two groups were lower than those before treatment(P < 0.05), and the levels of CRP, IL-6, TNF-α and IFN-γ in study group were lower than those in control group(P < 0.05 to P < 0.01). ConclusionsOn the basis of routine symptomatic treatment, the adjuvant therapy of methylprednisolone sodium succinate can effectively improve the clinical symptoms, promote the decline of inflammatory factors, reduce the inflammatory response, and has significant effects in children with severe mycoplasma pneumonia. -
表 1 2组患儿临床症状改善情况比较(x±s)
分组 n 退热时间/d 咳嗽消失时间/d 肺部啰音消失时间/d 观察组 30 1.40±0.75 3.31±1.28 2.27±0.69 对照组 30 3.11±1.24 4.35±1.30 4.52±1.39 t — 7.26 3.78 7.94 P — < 0.01 < 0.01 < 0.01 表 2 2组患儿炎性因子水平比较(x±s)
分组 n CRP/(mg/L) IL-6/(ng/L) TNF-α/(mg/L) IFN-γ/(ng/L) 治疗前 研究组 30 45.49±10.15 17.04±2.28 2.20±0.14 102.58±16.35 对照组 30 45.73±9.94 17.23±2.09 2.21±0.17 100.94±15.84 t — 0.09 0.34 0.25 0.39 P — >0.05 >0.05 >0.05 >0.05 治疗后 研究组 30 12.7±3.5* 7.21±0.66* 1.31±0.10* 82.89±11.06* 对照组 30 17.4±5.7* 11.32±1.07* 1.75±0.13* 90.12±13.87* t — 3.85 17.91 14.69 2.23 P — < 0.01 < 0.01 < 0.01 < 0.05 组内配对t检验:*P < 0.05 -
[1] 赵红英. 不同剂量甲泼尼龙琥珀酸钠治疗小儿重症支原体肺炎的临床疗效[J]. 儿科药学杂志, 2019, 25(2): 34. [2] 祝国强. 不同剂量甲泼尼龙琥珀酸钠与阿奇霉素对老年重症支原体肺炎患者的疗效及其对临床症状与炎症因子水平的影响[J]. 抗感染药学, 2018, 15(7): 1239. [3] 袁苏平. 甲泼尼龙琥珀酸钠联合阿奇霉素治疗重症支原体肺炎患儿[J]. 实用中西医结合临床, 2018, 18(6): 42. [4] 江载芳, 申昆玲, 诸福棠. 实用儿科学(上册)[M]. 8版. 北京: 人民卫生出版社, 2015: 1253. [5] YANG Y, ZHANG X, ZHOU C, et al. Elevated immunoreactivity of RANTES and CCR1 correlate with the severity of stages and dysmenorrhea in women with deep infiltrating endometriosis[J]. Acta Histochemica: Zeitschrift fur Histologische Topochemie, 2013, 115(5): 247. [6] GOVATATI S, KODATI VL, DEENADAVAL M, et al. Mutations in the PTEN tumor gene and risk of endometriosis: A case-control study[J]. Hum Reprod, 2014, 29(2): 378. [7] 杨波. 甲泼尼龙琥珀酸钠辅助治疗小儿重症支原体肺炎的临床疗效分析[J]. 航空航天医学杂志, 2015, 26(10): 1240. doi: 10.3969/j.issn.2095-1434.2015.10.035 [8] CHANG JH, AU HK, LEE WC, et al. Expression of the pluripotent transcription factor OCT4 promotes cell migration in endometriosis[J]. Fertil Steril, 2016, 99(5): 656. [9] JOWICZ AP, BROWN JK, MCDONALD SE, et al. Characterization of the temporal and spatial expression of a disintegrin and metalloprotease 17 in the human endometrium and fallopian tube[J]. Reprod Sci, 2016, 20(11): 592. [10] NEPOMNYASHCHIKH LM, LUSHNIKOVA EL, MOLODYKH OP, et al. Immunocytochemical analysis of proliferative activity of endometrial and myometrial cell populations in focal and stromal adenomyosis[J]. Bull Exp Biol Med, 2017, 155(4): 341. [11] 李明, 黄叶青. 小剂量甲泼尼龙琥珀酸钠与泼尼松联合治疗小儿难治性肺炎支原体肺炎的疗效[J]. 中国医学创新, 2015, 12(9): 10. doi: 10.3969/j.issn.1674-4985.2015.09.004 [12] SAARE M, SORITSA D, VAIDLA K, et al. No evidence of somatic DNA copy number alterations in eutopic and ectopic endometrial tissue in endometriosis[J]. Hum Reprod, 2018, 27(6): 647.